Agios PharmaceuticalsFRA:8AP +3.23%44 PB Ratio is 0.90 as of Jun. 26, 2026, which is 80% below its 10-year median of 4.52. GuruFocus rates FRA:8AP with a GF Score™ of 44/100 and a GF Value™ of €70.71 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,233 Biotechnology companies, Agios Pharmaceuticals ranks better than 85.73% on this metric.
The historical rank and industry rank for Agios Pharmaceuticals's PB Ratio or its related term are showing as below:
FRA:8AP'
s PB Ratio Range Over the Past 10 Years
Min: 0.62 Med: 4.52 Max: 10.92
Current: 0.89
During the past 13 years, Agios Pharmaceuticals's highest PB Ratio was 10.92. The lowest was 0.62. And the median was 4.52.
FRA:8AP's PB Ratio is ranked better than 85.73% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs FRA:8AP: 0.89
During the past 12 months, Agios Pharmaceuticals's average Book Value Per Share Growth Rate was 61.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 0.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 20.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 12.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Agios Pharmaceuticals was 36.00% per year. The lowest was -12.40% per year. And the median was 6.60% per year.
Back to Basics: PB Ratio
Agios Pharmaceuticals (FRA:8AP) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Agios Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agios Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Agios Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Agios Pharmaceuticals (FRA:8AP) has a PB Ratio of 0.90 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Agios Pharmaceuticals and its competitors. This is 80% below median its historical median of 4.52. Over the past decade, Agios Pharmaceuticals' PB Ratio has ranged from 0.62 to 10.92. According to the industry distribution chart, Agios Pharmaceuticals ranks #176 out of 1233 companies in the Biotechnology industry, placing it in the top 14.3%.
Is Agios Pharmaceuticals' PB Ratio too high?
Agios Pharmaceuticals' current PB Ratio of 0.90 is 80% below median its 10-year median of 4.52. Over the past 10 years, this metric has ranged from a low of 0.62 to a high of 10.92. The Biotechnology industry median PB Ratio is 2.80. Agios Pharmaceuticals' value of 0.90 is 67.9% below this industry median. Based on the distribution chart, Agios Pharmaceuticals ranks #176 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Agios Pharmaceuticals has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Agios Pharmaceuticals' PB Ratio compare to CAPR and SNDX?
According to the Biotechnology industry distribution chart, Agios Pharmaceuticals ranks #176 out of 1233 companies for PB Ratio. This places Agios Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Agios Pharmaceuticals' value of 0.90 is 67.9% below this benchmark. Historically, Agios Pharmaceuticals' own PB Ratio has ranged from 0.62 to 10.92 over the past decade. While the company's 10-year median is 4.52 vs. the industry median of 2.80, Agios Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Agios Pharmaceuticals's current PB Ratio of 0.90 is 67.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Agios Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Agios Pharmaceuticals's current PB Ratio is 0.90, which is 80% below median its own 10-year median of 4.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agios Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Agios Pharmaceuticals (FRA:8AP) is currently considered Possible Value Trap. The stock's GF Value™ is €70.71, compared to a current price of €32.00 — trading 54.7% below its estimated fair value. The current PB Ratio is 0.90, which is 80% below median its 10-year median of 4.52 and 67.9% below the Biotechnology industry median of 2.80. Agios Pharmaceuticals' overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Agios Pharmaceuticals (FRA:8AP), the current PB Ratio is 0.90 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agios Pharmaceuticals (FRA:8AP) Overvalued in 2026?
Based on GuruFocus' analysis, Agios Pharmaceuticals stock appears to be undervalued.
The current stock price of €32.00 is trading 54.7% below its estimated GF Value™ of €70.71.
GuruFocus considers Agios Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:8AP:
PB Ratio: 0.90 (80% below median its 10-year median of 4.52)
GF Value™: €70.71 vs. price of €32.00 (54.7% below fair value)
Industry Position: 67.9% below the Biotechnology median (#176 of 1233)
No single metric tells the full story. See the FRA:8AP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
44GF Score
Get the complete analysis for FRA:8AP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8AP has been successfully added to your 
